Clinical diagnostic value of plasma sHLA-G antigen in cervical cancer and precancerous lesion
10.3969/j.issn.1673-4130.2015.07.011
- VernacularTitle:血清可溶性白细胞G抗原在宫颈癌及癌前病变的临床诊断意义
- Author:
Meiling TIAN
;
Qingle LU
- Publication Type:Journal Article
- Keywords:
serum soluble human leukocyte antigen-G;
cervical carcinoma;
precancerous lesion
- From:
International Journal of Laboratory Medicine
2015;(7):889-891
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical diagnostic valve of serum soluble human leukocyte antigen‐G (sHLA‐G) in cervical cancer and precancerous lesion cervical intraepithelial neoplasia(CIN) .Methods The serum sHLA‐G level was detected by using ELISA and serum TA‐4 and SCC‐Ag levels were detected by using the light‐emitting electrochemical immunoassay method detec‐ting in 230 cases of cervical carcinoma ,120 cases of CIN and 30 healthy volunteers .The differences among various groups and their relationship with the clinicopathological features of cervical cancer were analyzed .Results (1) The comparison of serum sHLA‐G , TA‐4 and SCC‐Ag levels :there were statistically significant differences in serum sHLA‐G level among various groups (P=0 .000);the serum sHLA‐G level in the cervical cancer group was significantly higher than that in the healthy control group ,CIN Ⅰgroup , CIN Ⅱ group and CIN Ⅲ group (P=0 .000 ,P=0 .000 ,P=0 .002 ,P=0 .006);which in the CIN Ⅲ group was significantly higher than that in the CIN Ⅰ group and the healthy control group (P=0 .001 ,P=0 .021) .There were statistically significant differences in serum TA‐4 level among various groups (P=0 .006);the serum TA‐4 level in the cervical cancer group was significantly higher than that in the healthy control group ,CIN Ⅰ group and CIN Ⅱ group (P=0 .003 ,P=0 .008 ,P=0 .018);which in the CIN Ⅲgroup was significantly higher than that in the healthy control group and the CIN Ⅰ group (P=0 .023 ,P=0 .031) .The differences of serum SCC‐Ag level among various groups had statistically significant differences (P=0 .000);which in the cervical cancer group was significantly higher than that in the healthy control group ,CIN Ⅰ group and CIN Ⅱ group (P=0 .000 ,P=0 .001 ,P=0 .007) , and which in the CIN Ⅲ group was significantly higher than that in the healthy control group and the CIN Ⅰ group (P=0 .013 , P=0 .021) .(2) The relationship between serum sHLA‐G and pathological features of cervical cancer :the serum sHLA‐G level had no significant correlation with the age ,tumor size and pathological type (P>0 .05) ,while serum sHLA‐G was closely related with the FIGO stages and lymph node metastasis (P=0 .008 ,P=0 .031) .The serum sHLA‐G level in the FIGO stage Ⅲ and Ⅳ was significantly higher than that in the FIGO stageⅠ and Ⅱ (U=7 .125 ,P=0 .008) ,and which in the patients with lymph node me‐tastasis was significantly higher than that without lymph node metastasis (U=4 .651 ,P=0 .031) .Conclusion The detection of ser‐um sHLA‐G level can contribute to the early diagnosis and disease condition evaluation of cervical cancer and CIN Ⅲ ,thus which is likely to become a new indicator of early diagnosis of cervical cancer .But its specificity with the occurrence of cervical cancer and precancerous lesion remains to be further investigated by related research .
